Classes
DEA Class; Rx
Common Brand Names; Thorazine
- Antipsychotics, Phenothiazine
Description
Primarily used as an antipsychotic; occastionally used for presurgical anxiolytic, as an antiemetic, and for treatment of intractable hiccups
Boxed warning regarding an increased risk of death in elderly patients with dementia
Indications
Indicated for the treatment of schizophrenia.
Contraindications
Hypersensitivity to phenothiazines
Coma, severe hypotension, severe central nervous system (CNS) depression, concurrent administration of large amounts of CNS depressants, subcortical brain damage, poorly controlled seizure disorder
Severe cardiovascular disease
Lactation
Adverse Effects
Extrapyramidal symptoms
Akathisia
Dystonia
Muscle stiffness
Neuroleptic malignant syndrome (NMS; infrequent but serious)
Parkinsonism
Tardive dyskinesia
Common
Anticholinergic effects
Sedation
Weight gain
Erectile dysfunction
Oligomenorrhea or amenorrhea
Less common
Cerebral edema, orthostatic hypotension (after IM injection), tachycardia
Agitation, anxiety, depression, dizziness, euphoria, headache, insomnia, poikilothermia, restlessness, weakness
Anorexia, constipation, dyspepsia, ileus
Lens opacities (prolonged use)
Uncommon
ECG changes
Photosensitivity
Pruritus
Galactorrhea
Ejaculatory disorder
Diarrhea
Blood dyscrasia
Rare
Seizure
Priapism
Cholestatic jaundice
Warnings
Avoid using in children with suspected Reye syndrome
Use caution in glaucoma, prostatic hypertrophy, stenosing peptic ulcer disease (PUD), history of NMS, Parkinson disease, hypocalcemia, renal or hepatic impairment, history of severe reaction to insulin or electroconvulsive therapy (ECT), history of seizures, asthma, respiratory tract infection, cardiovascular disease, myelosuppression
Risk of extrapyramidal symptoms (EPS), NMS, hypotension
Significant hypotension may occur, especially with parenteral administration; hypotension may be particularly severe in patients with pheochromocytoma or mitral insufficiency; in case of severe hypotension, treat with norepinephrine or phenylepinephrine, and do not use epinephrine or dopamine
May alter cardiac conduction; life threatening arrhythmias reported with therapeutic doses of phenothiazines; may cause QT prolongation and subsequent torsade de pointes; avoid use in patients diagnosed or suspected congenital long QT syndrome
May cause anticholinergic effects; use caution in patients with paralytic ileus, gastrointestinal motility, urinary retention, xerostomia, or visual problems
Agranulocytosis, leukopenia, and neutropenia reported with antipsychotic use; periodic blood count assessment recommended in patients with history of risk factors, including history of drug-induced leuko/neutropenia or preexisting low WBC
Esophageal dysmotility and aspiration reported with antipsychotic use; use caution in patients at risk of pneumonia
May cause extrapyramidal symptoms, including akathisia, acute dystonic reactions, and pseudoparkinsonism, and tardive dyskinesia; risk of dystonia greater with increased doses
Therapy is associated with increased prolactin levels; significance unknown
May cause pigmentary retinopathy, and lenticular and corneal deposits with prolonged therapy
May cause orthostatic hypotension; use caution in patients with risk factors, including patients who do not tolerate transient hypotensive episodes such as hypovolemia, cerebrovascular disease, cardiovascular disease, or medicatioin predisposing to hypotension/bradycardia
May impair physical or mental abilities due to sedating properties; use caution when operating heavy machinery
Depresses hypothalamic thermoregulatory mechanism; exposure to extreme temperatures may cause hypo- or hyperthermia
Antiemetic effect may obscure toxicity of chemotherapeutic drugs
Anticholinergic antiparkinsonian agent may be needed to counter EPS
Strong anticholinergic agent and alpha blocker
Potential for priapism
US Food and Drug Administration (FDA) warning regarding off-label use for dementia in elderly (see Black Box Warnings)
Pregnancy and Lactation
Pregnancy category: C; neonates exposed to antipsychotic drugs during 3rd trimester of pregnancy are at risk for EPS or withdrawal symptoms after delivery; these complications vary in severity, with some being self-limited and others necessitating ICU support and prolonged hospitalization
Lactation: Drug enters breast milk; not recommended (American Academy of Pediatrics [AAP] states that this is “of concern”)
Maximum Dosage
1000 mg/day PO; up to 2000 mg/day PO for short periods. Debilitated patients require lower total daily dosages.
1000 mg/day PO. Debilitated patients require lower total daily dosages.
1000 mg/day PO; up to 2000 mg/day PO for short periods. Debilitated patients require lower total daily dosages.
5—12 years (weight 22.7—45.5 kg): 100—200 mg/day PO or 75 mg/day IM.
1—4.9 years (weight < 22.7 kg): 50 mg/day PO or 40 mg/day IM.
>= 6 months (weight < 22.7 kg): 50 mg/day PO or 40 mg/day IM.
How supplied
Chlorpromazine hydrochloride
tablet
- 10mg
- 25mg
- 50mg
- 100mg
- 200mg
injectable solution
- 25mg/mL